Market Cap
$7.5M
INM
InMed Pharmaceuticals Inc.
$1.34 ▼ -0.74%
Prev close $1.35Market cap$7.5M
Insider Buying Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on INM right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
3 funds
Inst. Value
$107.2K
Inst. Activity
0 buys / 1 sells
Insider Activity
$1.3M buy / $0.00 sell
Insider Net $
$1.3M
Social Sentiment
50° Neutral
SEC Reports
13
Price chart 30d -0.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 listing_status
Listing Status: INM — Deficient (was Normal)
InMed Pharmaceuticals Inc. - Common Shares | Nasdaq Financial Status Indicator N → D
Sep 16, 2026 Insider
ADAR1 Capital Management, LLC bought 8,340 shares
10%+ Owner @ $1.29 ($10.8K)
Sep 15, 2026 Insider
ADAR1 Capital Management, LLC bought 54,256 shares
10%+ Owner @ $1.30 ($70.4K)
Sep 14, 2026 Insider
Sep 9, 2026 SEC ADAR1 Capital Management, LLC bought 28,505 shares
10%+ Owner @ $1.29 ($36.9K)
InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on
425 — Impact 6/10
InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal se
8-K — Impact 6/10
InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics. The deal is structur
S-4 — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — TRIM
26,084 shares ($40.4K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Jan 1, 2023 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Dec 1, 2022 | 0 | 0 | 3 | 4 | 1 | 0% | |
| Nov 1, 2022 | 0 | 0 | 3 | 4 | 1 | 0% |
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 2 bullish, 7 bearish, 1 mixed, 3 neutral · avg impact 6.5/10.
NEUTRAL4256/10
InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a
Sep 9, 2026
BEARISH8-K6/10
InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics
Jul 10, 2026
BEARISHS-47/10
InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics.
Jul 2, 2026
BULLISHCLUSTER7/10
Two 10% owners (Vivo Opportunity, LLC and ADAR1 Capital Management, LLC) purchased a combined $189K
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
listing_status
Listing Status: INM — Deficient (was Normal)
InMed Pharmaceuticals Inc. - Common Shares | Nasdaq Financial Status Indicator N → D
Sep 21, 2026
earnings_calendar
INM Q4 2026 Earnings Scheduled — 2026-09-21
May 20, 2026
ftd
FTD: INM — 1,137,456 shares ($1.8M) failed to deliver
Settlement: 20260520, Price: $1.60, FTD Value: $1,819,929.6, INMED PHARMACEUTICALS INC COM
May 19, 2026
short_volume
Short Volume: INM — 55.1% short (17.5M / 31.8M)
Short: 17,504,441 | Exempt: 201,281 | TRF Vol: 31,780,457 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
INM Q3 2026 Earnings Scheduled — 2026-05-11
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own INM (from quarterly 13F filings) and who is adding or trimming.
3 institutional holders with $107.2K total value (69,164 shares) as of 2026-Q2. Top holders: JANE, CITADEL, Federation. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 43,078 | $66.8K | 62.3% | — |
| CITADEL ADVISORS LLC | 26,084 | $40.4K | 37.7% | TRIM -44.5% |
| Federation des caisses Desjardins du Quebec | 2 | $4.00 | 0.0% | DOUBLED +100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | TRIM | 46,973 | 26,084 | -44.5% | $40.4K |
| UBS Group AG | DOUBLED | 377 | 8,068 | +2040.1% | $5.2K |
| Federation des caisses Desjardins du Quebec | DOUBLED | 1 | 2 | +100.0% | $4.00 |
| UBS Group AG | ADD | 6,106 | 7,762 | +27.1% | $25.2K |
| UBS Group AG | TRIM | 10,408 | 6,106 | -41.3% | $12.6K |
| CITADEL ADVISORS LLC | DOUBLED | 12,097 | 56,666 | +368.4% | $13.3K |
| HRT FINANCIAL LP | DOUBLED | 15,996 | 38,369 | +139.9% | $8.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 37 transactions. Net $1.3M — $1.3M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 8,340 | $1.29 | $10.8K |
| Sep 15, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 54,256 | $1.30 | $70.4K |
| Sep 14, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 28,505 | $1.29 | $36.9K |
| Jul 16, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 19 | $1.55 | $29.45 |
| Jul 16, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 2 | $1.55 | $3.10 |
| Jul 15, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 13,761 | $1.55 | $21.3K |
| Jul 15, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 1,389 | $1.55 | $2.2K |
| Jul 15, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 1,000 | $1.56 | $1.6K |
| Jul 14, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 4,882 | $1.55 | $7.6K |
| Jul 14, 2026 | Vivo Opportunity, LLC | 10%+ Owner | BUY | 493 | $1.55 | $764.15 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INM.
Shares short
15,876
Settlement Sep 15, 2026
Change vs prior
-48.4%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.3%
Estimate — not % of float
All INM filing & press-release reports (13)
- 425 reportSep 9, 2026
- 8-K reportJul 10, 2026
- S-4 reportJul 2, 2026
- CLUSTER reportJun 11, 2026
- 8-K reportJun 10, 2026
- 425 reportMay 19, 2026
- 8-K reportMay 19, 2026
- 8-K reportMay 19, 2026
- 8-K reportApr 27, 2026
- 8-K reportApr 3, 2026
- 424B5 reportApr 3, 2026
- EFFECT reportMar 31, 2026
- S-3 reportMar 20, 2026